Lasala, together with the company`s Scientific Director and cell biologist Jose Minguell, PhD, treated 33 patients during the Phase I and Phase II safety/efficacy clinical trials using a combination of the patient`s own endothelial progenitor cells (EPCs) and mesenchymal stem cells (MSCs). A total of 40 patients will have finalized their studies by the end of this year.
TCA Cellular Therapy is the only company in the world utilizing two different types of adult stem cells to treat Peripheral Vascular Disease and Peripheral Arterial Disease ( PVD / PAD ). The formation of new mature blood vessels with the ability to appropriate blood supply requires participation of several types of adult stem cells and growth factors. "We are examining and proving Dr. Minguell's theory that it takes a combination of cells to grow new stable blood vessels that can regenerate and stimulate blood circulation," stated Lasala.
The adult stem cells, obtained through bone marrow aspiration, were separated, multiplied, mixed and infused in areas with damaged blood vessels to develop mature stable vessel formation in ischemic limbs.
According to Lasala, there were no adverse effects as a result of the infusions. All of the patients participating in the program have experienced improvement in their walking tests, ankle brachial pressure index, oxygen pressure, angiography and quality of life. Several of the patients were spared from amputation. The TCA Cellular Therapy combination cell product that was injected in areas with damaged blood vessels developed mature stable vessel formation in ischemic limbs, improving circulation, non-healing ulcers, gangrene and pain.
"The similarity in the recovery of our patients is pro
Copyright©2009 Vocus, Inc.
All rights reserved